Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?

Arthritis Research and Therapy

Volumn 14, Issue 5, 2012, Pages

  Saad, Carla G S ^a   Ribeiro, Ana C M ^a   Moraes, Julio C B ^a   Takayama, Liliam ^a   Goncalves, Celio R ^a   Rodrigues, Marcelo B ^a   de Oliveira, Ricardo M ^b   Silva, Clovis A ^a   Bonfa, Eloisa ^a   Pereira, Rosa M R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b RDO Diagnósticos Médicos ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; SCLEROTIN; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; LRP6 PROTEIN, HUMAN; SOST PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ANKYLOSING SPONDYLITIS QUALITY OF LIFE; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BATH ANKYLOSING SPONDYLITIS METROLOGY INDEX; BONE DENSITOMETRY; BONE DENSITY; BONE RADIOGRAPHY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HIGH RISK PATIENT; HORMONE DETERMINATION; HUMAN; INFLAMMATION; MALE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RISK FACTOR; SEX RATIO; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; GENETIC MARKER; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SPONDYLITIS, ANKYLOSING; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CASE-CONTROL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; INFLAMMATION; LOGISTIC MODELS; LONGITUDINAL STUDIES; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-6; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867325736     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4055     Document Type: Article

References (35)

1. Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A. Ankylosing spondylitis: an overview. Ann Rheum Dis 2002, 61(Suppl 3):iii8-18. 1766729, 12381506.
2. Maksymowych WP. Biomarkers in spondyloarthritis: from pathophysiology to disease assessment. Joint Bone Spine 2012, 79:4-6. 10.1016/j.jbspin.2011.09.018, 22119346.
3. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007, 13:156-163. 10.1038/nm1538, 17237793.
4. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006, 116:1202-1209. 10.1172/JCI28551, 1451219, 16670761.
5. Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 2009, 60:3257-3262. 10.1002/art.24888, 19877044.
6. Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 2010, 62:150-158. 10.1002/art.27231, 20039407.
7. Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2010, 69:592-597. 10.1136/ard.2008.102046, 19304568.
8. Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H, Baraliakos X, Listing J, Rudwaleit M, Schett G, Sieper J. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 2012, 71:572-574. 10.1136/annrheumdis-2011-200216, 22186710.
9. François RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheum Dis 2006, 65:713-720. 10.1136/ard.2005.037465, 1798185, 16249231.
10. Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ. Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res 2009, 24:1434-1449. 10.1359/jbmr.090305, 19292615.
11. Qadir AS, Lee HL, Baek KH, Park HJ, Woo KM, Ryoo HM, Baek JH. Msx2 is required for TNF-α-induced canonical Wnt signaling in 3T3-L1 preadipocytes. Biochem Biophys Res Commun 2011, 408:399-404. 10.1016/j.bbrc.2011.04.029, 21514273.
12. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904. 10.1136/ard.2011.151027, 3086052, 21540199.
13. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sörensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002, 359:1187-1193. 10.1016/S0140-6736(02)08215-6, 11955536.
14. Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
15. Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, . Enbrel Ankylosing Spondylitis Study Group Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003, 48:3230-3236. 10.1002/art.11325, 14613288, Enbrel Ankylosing Spondylitis Study Group.
16. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC, . ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146. 10.1002/art.21913, 16802350, ATLAS Study Group.
17. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005, 64:1462-1466. 10.1136/ard.2004.033472, 1755223, 15778240.
18. van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, Lin SL, Tsuji W, Davis JC. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008, 58:1324-1331. 10.1002/art.23471, 18438853.
19. van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J, . Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008, 58:3063-3070. 10.1002/art.23901, 18821688, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
20. van der Heijde D, Salonen D, Weissman BN, Landewé R, Maksymowych WP, Kupper H, Ballal S, Gibson E, Wong R, . Canadian (M03-606) study group; ATLAS study group Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009, 11:R127. 10.1186/ar2794, 2745811, 19703304, Canadian (M03-606) study group; ATLAS study group.
21. Braun J, Baraliakos X. Imaging of axial spondyloarthritis including ankylosing spondylitis. Ann Rheum Dis 2011, 70(Suppl 1):i97-103. 10.1136/ard.2010.140541, 21339229.
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368. 10.1002/art.1780270401, 6231933.
23. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewé R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68(Suppl 2):ii1-44. 10.1136/ard.2008.104018, 19433414.
24. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res 2011, 26:373-379. 10.1002/jbmr.217, 3179347, 20721932.
25. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005, 64:127-129. 10.1136/ard.2004.020503, 1755183, 15051621.
26. Lewiecki EM, Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Silverman S, . International Society for Clinical Densitometry Report of the International Society for Clinical Densitometry 2007 Adult Position Development Conference and Official Positions. South Med J 2008, 10:735-739. International Society for Clinical Densitometry.
27. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-889. 10.1152/ajprenal.00360.2010, 20685823.
28. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int 2012, 23:1171-1176. 10.1007/s00198-010-1525-6, 21305266.
29. Ardawi MS, Al-Kadi HA, Rouzi AA, Qari MH. Determinants of serum sclerostin in healthy pre- and postmenopausal women. J Bone Miner Res 2011, 26:2812-2822. 10.1002/jbmr.479, 21812027.
30. Bonewald LF. The amazing osteocyte. J Bone Miner Res 2011, 26:229-238. 10.1002/jbmr.320, 3179345, 21254230.
31. Paszty C, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. J Bone Miner Res 2010, 25:1897-1904. 10.1002/jbmr.161, 20564241.
32. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005, 280:19883-19887. 10.1074/jbc.M413274200, 15778503.
33. Heiland GR, Zwerina K, Baum W, Kireva T, Distler JH, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis 2010, 69:2152-2159. 10.1136/ard.2010.132852, 20858621.
34. Schett G. Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations. Am J Med Sci 2011, 341:269-1271. 10.1097/MAJ.0b013e31820f8b29, 21358309.
35. Appel H, Kuhne M, Spiekermann S, Ebhardt H, Grozdanovic Z, Köhler D, Dreimann M, Hempfing A, Rudwaleit M, Stein H, Metz-Stavenhagen P, Sieper J, Loddenkemper C. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006, 54:2845-2851. 10.1002/art.22060, 16947385.